Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial

医学 氟尿嘧啶 奥沙利铂 养生 全直肠系膜切除术 放化疗 外科 结直肠癌 内科学 化疗方案 化疗 放射治疗 临床终点 随机对照试验 癌症
作者
Claus Rödel,Ullrich Graeven,Rainer Fietkau,Werner Hohenberger,Torsten Hothorn,Dirk Arnold,Ralf‐Dieter Hofheinz,Michael Ghadimi,Richard Viebahn,Marga Lang-Welzenbach,Hans-Rudolf Raab,Christian Wittekind,Philipp Ströbel,Ludger Staib,Martin Wilhelm,Gerhard G. Grabenbauer,H.W. Hoffmanns,Fritz Lindemann,Anke Schlenska‐Lange,Gunnar Folprecht,Rolf Sauer,Torsten Liersch
出处
期刊:Lancet Oncology [Elsevier]
卷期号:16 (8): 979-989 被引量:625
标识
DOI:10.1016/s1470-2045(15)00159-x
摘要

Preoperative chemoradiotherapy with infusional fluorouracil, total mesorectal excision surgery, and postoperative chemotherapy with fluorouracil was established by the German CAO/ARO/AIO-94 trial as a standard combined modality treatment for locally advanced rectal cancer. Here we compare the previously established regimen with an investigational regimen in which oxaliplatin was added to both preoperative chemoradiotherapy and postoperative chemotherapy.In this multicentre, open-label, randomised, phase 3 study we randomly assigned patients with rectal adenocarcinoma, clinically staged as cT3-4 or any node-positive disease, to two groups: a control group receiving standard fluorouracil-based combined modality treatment, consisting of preoperative radiotherapy of 50·4 Gy in 28 fractions plus infusional fluorouracil (1000 mg/m(2) on days 1-5 and 29-33), followed by surgery and four cycles of bolus fluorouracil (500 mg/m(2) on days 1-5 and 29); or to an investigational group receiving preoperative radiotherapy of 50·4 Gy in 28 fractions plus infusional fluorouracil (250 mg/m(2) on days 1-14 and 22-35) and oxaliplatin (50 mg/m(2) on days 1, 8, 22, and 29), followed by surgery and eight cycles of oxaliplatin (100 mg/m(2) on days 1 and 15), leucovorin (400 mg/m(2) on days 1 and 15), and infusional fluorouracil (2400 mg/m(2) on days 1-2 and 15-16). Randomisation was done with computer-generated block-randomisation codes stratified by centre, clinical T category (cT1-3 vs cT4), and clinical N category (cN0 vs cN1-2) without masking. The primary endpoint was disease-free survival, defined as the time between randomisation and non-radical surgery of the primary tumour (R2 resection), locoregional recurrence after R0/1 resection, metastatic disease or progression, or death from any cause, whichever occurred first. Survival and cumulative incidence of recurrence analyses followed the intention-to-treat principle; toxicity analyses included all patients treated. Enrolment of patients in this trial is completed and follow-up is ongoing. This study is registered with ClinicalTrials.gov, number NCT00349076.Of the 1265 patients initially enrolled, 1236 were assessable (613 in the investigational group and 623 in the control group). With a median follow-up of 50 months (IQR 38-61), disease-free survival at 3 years was 75·9% (95% CI 72·4-79·5) in the investigational group and 71·2% (95% CI 67·6-74·9) in the control group (hazard ratio [HR] 0·79, 95% CI 0·64-0·98; p=0·03). Preoperative grade 3-4 toxic effects occurred in 144 (24%) of 607 patients who actually received fluorouracil and oxaliplatin during chemoradiotherapy and in 128 (20%) of 625 patients who actually received fluorouracil chemoradiotherapy. Of 445 patients who actually received adjuvant fluorouracil and leucovorin and oxaliplatin, 158 (36%) had grade 3-4 toxic effects, as did 170 (36%) of 470 patients who actually received adjuvant fluorouracil. Late grade 3-4 adverse events in patients who received protocol-specified preoperative and postoperative treatment occurred in 112 (25%) of 445 patients in the investigational group, and in 100 (21%) of 470 patients in the control group.Adding oxaliplatin to fluorouracil-based neoadjuvant chemoradiotherapy and adjuvant chemotherapy (at the doses and intensities used in this trial) significantly improved disease-free survival of patients with clinically staged cT3-4 or cN1-2 rectal cancer compared with our former fluorouracil-based combined modality regimen (based on CAO/ARO/AIO-94). The regimen established by CAO/ARO/AIO-04 can be deemed a new treatment option for patients with locally advanced rectal cancer.German Cancer Aid (Deutsche Krebshilfe).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
LayM完成签到,获得积分20
4秒前
4秒前
可爱的函函应助AoAoo采纳,获得10
6秒前
徐涛完成签到,获得积分10
6秒前
monica项发布了新的文献求助10
6秒前
zhw完成签到,获得积分10
6秒前
阳光he完成签到,获得积分10
9秒前
Ooo发布了新的文献求助10
10秒前
番茄小超人2号完成签到 ,获得积分10
11秒前
litboy完成签到,获得积分10
11秒前
FashionBoy应助monica项采纳,获得10
11秒前
卷不动了发布了新的文献求助10
11秒前
Ava应助1874采纳,获得10
11秒前
12秒前
沙河口大长硬完成签到,获得积分10
13秒前
桔梗完成签到,获得积分10
15秒前
16秒前
能干的茗完成签到,获得积分10
16秒前
17秒前
17秒前
AoAoo发布了新的文献求助10
20秒前
卷不动了完成签到,获得积分10
20秒前
22秒前
22秒前
小芳芳发布了新的文献求助10
23秒前
MY20240406发布了新的文献求助10
23秒前
Remote发布了新的文献求助20
26秒前
xiao完成签到,获得积分10
27秒前
Owen应助lee采纳,获得10
27秒前
孔雀翎完成签到,获得积分10
27秒前
疯狂的冬瓜完成签到,获得积分10
28秒前
丘比特应助1874采纳,获得10
28秒前
善学以致用应助桃桃采纳,获得10
29秒前
Ohoooo完成签到,获得积分10
30秒前
Hello应助卡卡罗特采纳,获得10
31秒前
A3000完成签到,获得积分10
32秒前
zho应助AoAoo采纳,获得10
33秒前
sanmu给mzb的求助进行了留言
34秒前
能干的茗关注了科研通微信公众号
35秒前
joo完成签到,获得积分10
35秒前
高分求助中
Evolution 10000
ISSN 2159-8274 EISSN 2159-8290 1000
Becoming: An Introduction to Jung's Concept of Individuation 600
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 500
The Kinetic Nitration and Basicity of 1,2,4-Triazol-5-ones 440
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3159748
求助须知:如何正确求助?哪些是违规求助? 2810660
关于积分的说明 7889023
捐赠科研通 2469717
什么是DOI,文献DOI怎么找? 1315035
科研通“疑难数据库(出版商)”最低求助积分说明 630738
版权声明 602012